{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:16:57Z","timestamp":1790835417476,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100019632","name":"Agence Regionale de Sante Provence-Alpes-Cote d'Azur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019632","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.therap.2023.03.008","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T12:15:07Z","timestamp":1678882507000},"page":"605-614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pr\u00e9vention des surdoses opio\u00efdes et diffusion de naloxone (programme POP)\u00a0: r\u00e9sultats d\u2019un \u00e9tat des lieux r\u00e9alis\u00e9 aupr\u00e8s des structures d\u2019addictologie"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8396-3667","authenticated-orcid":false,"given":"Salim","family":"Mezaache","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Turlure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Fredon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maela","family":"Le Brun Gadelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Frauger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2023.03.008_bib0135","doi-asserted-by":"crossref","first-page":"290","DOI":"10.15585\/mmwr.mm6911a4","article-title":"Drug and opioid-involved overdose deaths\u00a0\u2013\u00a0United States, 2017\u20132018","volume":"69","author":"Wilson","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.therap.2023.03.008_bib0140","unstructured":"World Health Organization Opioid overdose. 2021. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/opioid-overdose. [Accessed 13 March 2023]"},{"key":"10.1016\/j.therap.2023.03.008_bib0145","unstructured":"R\u00e9seau fran\u00e7ais d\u2019addictovigilance D\u00e9c\u00e8s en relation avec l\u2019abus de m\u00e9dicaments et de substances. Principaux r\u00e9sultats enqu\u00eate DRAMES 2019. 2021. https:\/\/addictovigilance.fr\/wp-content\/uploads\/2021\/08\/Plaquette-DRAMES-2019.pdf. [Accessed 13 March 2023 (2 pp.)]"},{"key":"10.1016\/j.therap.2023.03.008_bib0150","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMra1202561","article-title":"Management of opioid analgesic overdose","volume":"367","author":"Boyer","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.therap.2023.03.008_bib0155","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/bmj.322.7291.895","article-title":"Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes","volume":"322","author":"Dettmer","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2023.03.008_bib0160","series-title":"Community management of opioid overdose","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.therap.2023.03.008_bib0165","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/ADM.0000000000000034","article-title":"A systematic review of community opioid overdose prevention and naloxone distribution programs","volume":"8","author":"Clark","year":"2014","journal-title":"J Addict Med"},{"key":"10.1016\/j.therap.2023.03.008_bib0170","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40621-015-0041-8","article-title":"Effectiveness of bystander naloxone administration and overdose education programs: a meta-analysis","volume":"2","author":"Giglio","year":"2015","journal-title":"Inj Epidemiol"},{"key":"10.1016\/j.therap.2023.03.008_bib0175","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/add.13326","article-title":"Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria","volume":"111","author":"McDonald","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.therap.2023.03.008_bib0180","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.therap.2018.07.001","article-title":"Int\u00e9r\u00eat de la mise \u00e0 disposition de la naloxone aupr\u00e8s des usagers de drogues pour le traitement d\u2019urgence de surdosage d\u2019opio\u00efdes","volume":"73","author":"Frauger","year":"2018","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.03.008_bib0185","unstructured":"R\u00e9seau fran\u00e7ais d\u2019addictovigilance Int\u00e9r\u00eat d\u2019une diffusion large de naloxone. 2021. https:\/\/addictovigilance.fr\/wp-content\/uploads\/2021\/12\/Bulletin-Naloxone-2021.pdf. [Accessed 13 March 2023 (2 pp)]"},{"key":"10.1016\/j.therap.2023.03.008_bib0190","unstructured":"R\u00e9seau fran\u00e7ais d\u2019addictovigilance Observation des produits psychotropes illicites ou d\u00e9tourn\u00e9s de leur utilisation m\u00e9dicamenteuse. Les principaux faits marquants 2021 OPPIDUM. 2021. https:\/\/addictovigilance.fr\/wp-content\/uploads\/2022\/09\/Plaquette-oppidum-2021.pdf. [Accessed 13 March 2023 (2 pp.)]"},{"key":"10.1016\/j.therap.2023.03.008_bib0195","unstructured":"JORF Arr\u00eat\u00e9 du 5 mai 2017 fixant la liste des m\u00e9dicaments pouvant \u00eatre dispens\u00e9s dans les centres d\u2019accueil et d\u2019accompagnement \u00e0 la r\u00e9duction des risques et des dommages pour usagers de drogues. 2017. https:\/\/www.legifrance.gouv.fr\/loda\/id\/JORFTEXT000034634951. [Accessed 13 March 2023]"},{"key":"10.1016\/j.therap.2023.03.008_bib0200","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.therap.2016.05.001","article-title":"Les 25\u00a0ans des centres d\u2019\u00e9valuation et d\u2019information sur la pharmacod\u00e9pendance-addictovigilance","volume":"71","author":"Micallef","year":"2016","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.03.008_bib0205","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1753-6405.2007.00114.x","article-title":"A health researcher's guide to qualitative methodologies","volume":"31","author":"Dew","year":"2007","journal-title":"Aust N Z J Public Health"},{"key":"10.1016\/j.therap.2023.03.008_bib0210","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.therap.2019.01.005","article-title":"Retour d\u2019exp\u00e9rience de deux CSAPA et enqu\u00eate nationale sur la naloxone intranasale (Nalscue\u00ae) dans la pr\u00e9vention des overdoses aux opio\u00efdes","volume":"74","author":"Lenglard","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.03.008_bib0215","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ypmed.2015.05.016","article-title":"Distribution of naloxone for overdose prevention to chronic pain patients","volume":"80","author":"Coe","year":"2015","journal-title":"Prev Med"},{"key":"10.1016\/j.therap.2023.03.008_bib0220","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.therap.2018.03.003","article-title":"Pratique de l\u2019ATU de cohorte de la naloxone intranasale (Nalscue\u00ae)\u00a0: mise en place dans un CSAPA parisien","volume":"73","author":"Barr\u00e9","year":"2018","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.03.008_bib0225","unstructured":"HAS Bon usage des m\u00e9dicaments opio\u00efdes : antalgie, pr\u00e9vention et prise en charge du trouble de l\u2019usage et des surdoses. 2022. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2022-03\/reco_opioides.pdf. [Accessed 13 March 2023 (72 pp.)]"},{"key":"10.1016\/j.therap.2023.03.008_bib0230","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12954-019-0328-0","article-title":"One opioid user saving another: the first study of an opioid overdose-reversal and naloxone distribution program addressing hard-to-reach drug scenes in Denmark","volume":"16","author":"Thylstrup","year":"2019","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.therap.2023.03.008_bib0235","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.socscimed.2017.03.013","article-title":"The social logic of naloxone: peer administration, harm reduction, and the transformation of social policy","volume":"180","author":"Faulkner-Gurstein","year":"2017","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.therap.2023.03.008_bib0240","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.addbeh.2018.03.011","article-title":"Naloxone formulation for overdose reversal preference among patients receiving opioids for pain management","volume":"86","author":"Dunn","year":"2018","journal-title":"Addict Behav"},{"key":"10.1016\/j.therap.2023.03.008_bib0245","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.therap.2022.01.006","article-title":"Proportion and conditions of use of intranasal take-home naloxone kits: a retrospective study in two French outpatient addiction centers, 2016\u20132020","volume":"77","author":"Chappuy","year":"2022","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.03.008_bib0250","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1526-4637.2005.00072.x","article-title":"Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool","volume":"6","author":"Webster","year":"2005","journal-title":"Pain Med"},{"key":"10.1016\/j.therap.2023.03.008_bib0255","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jsat.2008.02.001","article-title":"Prescription Opioid Misuse Index: a brief questionnaire to assess misuse","volume":"35","author":"Knisely","year":"2008","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.therap.2023.03.008_bib0130","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000511770","article-title":"Validation of the Opioid Overdose Knowledge (OOKS) and Attitudes (OOAS) Scales in French, Spanish, and German Languages, among a sample of opioid users","volume":"27","author":"Laconi","year":"2021","journal-title":"Eur Addict Res"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723000574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723000574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:55:55Z","timestamp":1758567355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595723000574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0040595723000574"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2023.03.008","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pr\u00e9vention des surdoses opio\u00efdes et diffusion de naloxone (programme POP)\u00a0: r\u00e9sultats d\u2019un \u00e9tat des lieux r\u00e9alis\u00e9 aupr\u00e8s des structures d\u2019addictologie","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2023.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}